ProCE Banner Activity

CE / CME

Treating to Eliminate HCV: Case Discussion

In this video capture of a roundtable session from the 2019 CCO Hepatitis Annual Meeting, expert faculty provide a case-based analysis of important considerations and strategies for overcoming remaining challenges to treating all individuals with HCV infection, with a focus on several key populations: persons who inject drugs, persons who are incarcerated, women who are pregnant, and patients with genotype 3 HCV infection and cirrhosis.

Pharmacists : 1.50 contact {hours} ({0.15} CEUs)

Physicians : maximum of 1.50 AMA PRA Category 1 {Credits}

Registered Nurses : 1.50 Nursing contact {hours}

Released: August 01, 2019

Expiration: July 31, 2020

No longer available for credit.

Share

Faculty

Jordan J. Feld

Jordan J. Feld, MD, MPH

Assistant Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Diseases
Sandra Rotman Centre for Global Health
Toronto, Ontario, Canada

Ira M. Jacobson

Ira M. Jacobson, MD

Vincent Astor Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
Weill Cornell Medical College
Attending Physician
Division of Gastroenterology and Hepatology
Department of Medicine
NewYork-Presbyterian Hospital
New York, New York

Paul Y. Kwo

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Marion G. Peters

Marion G. Peters, MD

Professor of Medicine
University of California, San Francisco
San Francisco, California

Nancy Reau

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Gilead

Janssen

Merck Oncology

ViiV Healthcare

Target Audience

This program is intended for hepatologists, gastroenterologists, infectious diseases clinicians, registered nurses, pharmacists, and other healthcare professionals involved in the care of patients with viral hepatitis.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement practical strategies for linking individuals from marginalized populations to HCV care when feasible
  • Integrate the results of clinical studies of approved HCV treatments into optimized patient management strategies for key underserved populations such as people who inject drugs
  • Apply key guidelines and study data to ensure appropriate HCV screening and management strategies during pregnancy

Disclosure

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME/CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Ira M. Jacobson, MD

Vincent Astor Professor of Medicine
Chief, Division of Gastroenterology and Hepatology
Department of Medicine
Weill Cornell Medical College
Attending Physician
Division of Gastroenterology and Hepatology
Department of Medicine
NewYork-Presbyterian Hospital
New York, New York

Ira M. Jacobson, MD, has disclosed that he has received consulting fees from AbbVie, Arrowhead, Assembly Biosciences, Bristol-Myers Squibb, Gilead Sciences, Intercept, Janssen, Merck, Novo Nordisk, Siemens, and Springbank and funds for research support from Assembly Biosciences, Bristol-Myers Squibb, Enanta, GENFIT, Gilead Sciences, and Janssen.

Faculty Disclosure

Primary Author

Jordan J. Feld, MD, MPH

Assistant Professor of Medicine
University of Toronto
Hepatologist
Toronto Centre for Liver Diseases
Sandra Rotman Centre for Global Health
Toronto, Ontario, Canada

Jordan J. Feld, MD, MPH, has disclosed that he has received consulting fees from Contravir, Enanta, and Roche and funds for research support from AbbVie, Gilead Sciences, and Janssen.

Paul Y. Kwo, MD

Professor of Medicine
Medical Director of Transplantation
Division of Medicine/Gastroenterology/Hepatology
Indiana University School of Medicine
Indianapolis, Indiana

Paul Y. Kwo, MD, has disclosed that he has received consulting fees from AbbVie, Conatus, Dova, Edigene, Eisai, Ferring, Gilead Sciences, Quest, and Surrozen; has received funds for research support from Allergan, Assembly, Gilead Sciences, La Jolla, and Target PharmaSolutions; and has ownership interest in Durect.

Marion G. Peters, MD

Professor of Medicine
University of California, San Francisco
San Francisco, California

Marion G. Peters, MD, FRACP, has disclosed that her spouse is employed by Hoffmann-La Roche.

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Nancy Reau, MD, has disclosed that she has received consulting fees from Abbott, AbbVie, Gilead Sciences, and Merck and funds for research support from Genfit, Intercept, and Shire.

Staff Disclosure

Staff

Jennifer M. Blanchette, Ph.D.

Clinical Editor
Clinical Care Options, LLC

Jennifer Blanchette, PhD, has no relevant conflicts of interest to report.

Edward King, M.A.

Vice President, Editorial
Clinical Care Options, LLC

Edward King, MA, has no relevant conflicts of interest to report.

Jenny Schulz, PhD

Associate Managing Editor, Hepatitis
Clinical Care Options, LLC

Jenny Schulz, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement

Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation

1.5 contact hours may be earned for successful completion of this activity.

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

This program is assigned ACPE Universal Activity 0797-9999-19-089-H01-P. This program is designated for up to 1.5 contact hours (0.15 CEUs) of continuing pharmacy education credit.

Type of Activity Application

For Pharmacists: Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

Disclosure of Unlabeled Use

The PIM planners and managers have nothing to disclose.

Charles E. Willis, Director of Continuing Education; Amanda Sewell, MBA, Manager of Continuing Education and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 01, 2019, through July 31, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in addressing the most important and most current challenges in viral hepatitis management by providing a tightly focused update on recent advances and key clinical issues encountered in the clinic.